Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma
Patients with metastatic bladder cancer have a median survival of only 13-14 months. Precision medicine using targeted therapy may improve survival. Here we investigated spatial and temporal tumour evolution and tumour heterogeneity in order to evaluate the potential use of targeted treatment of metastatic bladder cancer. We performed a proof-of-concept study by whole exome sequencing of multiple tumour regions (n=22) from three patients with metastatic bladder cancer. DNA from primary and metastatic tumour biopsies was analysed for mutations using Mutect and potential therapeutic targets were identified.
Source: Molecular Oncology - Category: Cancer & Oncology Authors: Mathilde B.H. Thomsen, Iver Nordentoft, Philippe Lamy, S øren Høyer, Søren Vang, Jakob Hedegaard, Michael Borre, Jørgen B. Jensen, Torben F. Ørntoft, Lars Dyrskjøt Source Type: research